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Objectives: As the emphasis on value of oncology agents grows, ASCO has released 
a framework proposing to evaluate the net health benefit of such therapies. This 
study aims to evaluate the application of the ASCO framework for all recently 
approved oncology therapies, including barriers and challenges that may be encoun-
tered. MethOds: Oncology drugs approved from January 2013 to May 2015 (N= 19) 
were obtained from the FDA website. Palliative therapies were excluded. Registrational 
trials (N= 31) for the corresponding drugs were identified from peer-reviewed publica-
tions. The Net Health Benefit (NHB) score worksheet was completed for each clinical 
trial as outlined in the ASCO advanced disease framework using Overall Survival (OS), 
Progression-Free Survival (PFS), Response Rate (RR), Toxicity, Palliation, and Treatment-
Free Interval. Issues encountered were catalogued for review. Results: 1 of 31 clinical 
trials was excluded due to lack of publication in peer-reviewed journals. An additional 
9 trials were excluded due to non-randomized trial design, resulting in 22 trials cor-
responding to 16 drugs. OS data was used for scoring in 59% of the remaining trials. 
PFS was used in 27% of the trials, and RR in 14% of the trials. Toxicity data was scored 
in 95% of the trials, palliation data in 77% of trials, and treatment-free interval data 
in 95% of the trials. The most common scoring issues encountered included median 
OS or PFS not reached (8/22) and incomplete palliation or treatment-free interval 
data (5/22). cOnclusiOns: Lack of peer-reviewed publications, non-randomized 
trial designs, and requisite clinical data resulted in methodological challenges that 
deterred application of the ASCO framework for recent oncology drugs. Lack of appro-
priate data may result in lower scores than could be recognized from the available 
evidence at time of market authorization.
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Objectives: France is one of the European countries that spends the most on oncol-
ogy drugs. In the context of a cost-constraint environment, Health Authorities highly 
scrutinize market access pathways for potentially costly medicines. This study aimed 
to conduct a review of the Transparency Committee (CT) opinions of antineoplas-
tic drugs indicated for the treatment of solid tumours to assess current trends in 
French health technology assessment (HTA), to confront experts with outcomes of 
this review and discuss foreseen challenges for HTA of future antineoplastic medi-
cines in France. MethOds: A review of CT opinions issued for all antineoplastic drugs 
indicated in the treatment of solid tumours and approved between 2009 and 2014 
was performed to assess current trends in French HTA. An expert board consultation 
was also conducted to capture critical issues on the future of antineoplastic drugs 
HTA. Results: Thirty-one drugs indicated for the treatment of solid tumors were 
identified. Targeted therapies represented 77% of all drugs. Initial CT assessments 
were available for 26 drugs. Efficacy /safety ratio predicted actual benefit (SMR), but 
not improvement in actual benefit (ASMR) ratings. Early access scheme for innova-
tive medicines did not impact ASMR score. Four key items in CT assessment were 
identified: (1) Clinical trial methodology; (2) Acceptance of progression-free survival 
as a valuable endpoint; (3) Transferability of clinical trials in clinical practice; (4) Lack 
of predictability of CT decisions. Experts pointed out the important development of 
personalized medicine in oncology raising many challenges in terms of strategic posi-
tioning, ethics and clinical trial design, to generate information expected from HTA 
perspective. cOnclusiOns: French system remains committed to its values and phi-
losophy (access of all innovations for everybody) which are threatened by the increas-
ing launch of innovative therapies and budget constraint. French HTA analysis decision 
model will have to evolve to cope with new challenges raised by oncology drugs.
PCN335
DiFFereNCes aND similarities iN hta: a ComParative aNalysis oF the 
DeCisioN-makiNg ProCesses For CaNCer Drugs aCross 4 CouNtries
Visintin E1, Nicod E2
1London School of Economics and Political Sciences, London, UK, 2London School of Economics and 
Political Science, London, UK
Objectives: To identify similarities and differences in HTA decision-making pro-
cesses and outcomes, and explore the criteria driving these decisions in different 
settings analysing a sample of cancer drugs. MethOds: This study applied a vali-
dated methodological framework built on a mixed methods approach to system-
atically compare HTA recommendations for a sample of 15 cancer drugs in four 
countries (England, Scotland, Sweden and France). All decision-making criteria were 
identified and compared at each stage of the decision-making process: the evidence 
appraised, its interpretation and influence on the final decision. Qualitative data 
collection and analysis was conducted using the NVivo software. Results: Across 
the sample, the same primary trials were generally appraised to determine the 
treatment’s clinical efficacy (93% common to all). From the same trials, heteroge-
neity was seen in the subgroup analyses (nsubgroupNICE= 25, nsubgroupHAS = 15, 
nsubgroupSMC= 11, nsubgroupTLV= 7) and number of endpoints considered (nend-
pointsNICE= 149, nendpointsHAS 100, nendpointsSMC= 105, nendpointsTLV= 15). All 
the primary trials were phase III, 57% of which were open-label. Direct comparators 
were the most commonly used (37%), the remainder being placebo (28%), standard 
care (13%), none (13%) and drugs in sequence (8%). The economic trials presented 
were the same across the agencies, where 53% used the same direct comparator. 
When interpreting the same trials, NICE raised the highest number of concerns 
(nuncertainNICE= 94 uncertainties), of which 76% were addressed by various means 
(74% by stakeholder input). SMC, HAS and TLV raised a lower number of uncer-
tainties with fewer being addressed (16% of nuncertainSMC= 80, 8% of nuncertain-
HAS= 38, and 9% of nuncertainTLV= 11). cOnclusiOns: This study enables to better 
understand the reasons for differences across countries, and whether we can learn 
from the different ways seen to assess value in different settings. Identifying those 
for the study. The interviews were recorded after participants’ written consent 
and were transcribed and content analyzed. Results: 23 women participated. 
Fear, panic, anger, and anxiety were the main feelings during the diagnosis. 
Chemotherapies were perceived as the most painful part of the treatment both 
physically and emotionally. Mastectomy and hair loss changed their image radi-
cally. Their husband and friends were the two most important sources of support 
and they felt that their relationships became stronger during the disease. The 
disease had a severe impact on patients’ families as well and a major concern 
among the participants was their children. At the time of the study, women evalu-
ated their experience positively. They attribute their disease to their previous 
way of life and they perceive it as a chance to move forward and put themselves 
first. During their journey they felt the need for psychological support but this 
was not always feasible due to economic barriers and lack of such services in the 
hospitals. cOnclusiOns: Breast cancer diagnosis is the beginning of a long and 
painful journey that brings changes to patients’ life. At the end however, most 
patients seem to embrace their disease which becomes part of their identity. 
Professional psychological support is necessary in all stages and needs to be part 
of the treatment process in Greece.
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Objectives: To identify decisions by the SMC using the PACE process since the 
scheme was introduced and identify issues that influence a successful out-
come. MethOds: Assessments that used the PACE process were identified from 
SMC briefing notes between May 2014 and June 2015. Key points expressed were 
classified into clinical issues or added value to the patient or carers. Results: 
Twenty assessments were identified that used the PACE process: 17 in oncology 
indications and one each in hypertension, infection in cystic fibrosis, and myelofi-
brosis/splenomegaly. Ten were accepted (seven with a patient access scheme [PAS]) 
– three that met orphan criteria, one that met end-of-life criteria, and six that met 
both. Five products were accepted with restrictions (four with a PAS) and five were 
rejected (one with a PAS). All assessments discussed clinical issues, including 
health-related benefits (17/20), health-related quality of life (HRQL) benefit related 
to symptoms (13/20), and reduction in adverse events (11/20). Sixteen provided 
data on the severity of the condition (impact on patients, carers and families, 
and/or assessment of severity); 9 characterized the unmet need; 13 considered 
the most appropriate position for the medicine in the pathway of care and/or 
identified specific patient groups. Seven assessments argued for added value to 
patients (convenience of treatment) and value to patient’s family and carers in 
terms of impact on family life (6), requirements for carers (2), and carers’ ability 
to work (1). cOnclusiOns: PACE assessments to date have largely focused on 
clinical issues and patient’s quality of life, with limited attention as yet to the 
benefit to patients’ families/carers. PACE appears to be meeting the SMC’s objec-
tive of providing a forum for patients and clinicians to present arguments regard-
ing the wider benefits of a drug that may not be easily captured in the standard 
assessment process.
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Objectives: This study estimates the burden of breast cancer (BC) on population 
health in Portugal in 2013. MethOds: The impact on health status was measured 
using the Disability Adjusted Life Years (DALYs). Years Lost due to Disability (YLD) 
were estimated following Kruijshaar and Barendreght (2004) and the European 
Disability Weights project. This model separates the BC patients into 5 different 
pathways: 1) survivors undergoing mastectomy or 2) breast-conserving surgery, 
3) non-survivors undergoing mastectomy or 4) breast conserving therapy, or 5) 
patients diagnosed with non-operable or disseminated disease. The model uses an 
incidence perspective giving to each pathway a different sequence of health states 
with specific disutility weights. Data from the Portuguese National and Regional 
Cancer Registries was used to estimate the incidence of BC in Portugal. Portuguese 
DRG Database was queried in order to identify incident cases undergoing surgery. 
The average total disease duration by age groups was approximated using DisMod II 
software. The Years of Life Lost (YLL) due to BC premature mortality were calculated 
based on data from the Portuguese Institute of Statistics using a social weighting 
function which places a greater value on a year lived as a young adult. Results: 
In Portugal 6.938 new cases of female BC were estimated. A total 1,646 deaths were 
caused by BC in the same year, which corresponds to 3.1% of the total female deaths 
in Portugal. The YLL caused by BC in 2013 totaled 13,425 representing 6.1% of YLL in 
the female population of the country. For 2013 the YLD estimated were 11,368. The 
total disease burden attributable to female BC is thus estimated at 24,793 DALY or 
453 DALY/100,000 women. cOnclusiOns: Breast cancer is an important cause of 
disease burden for Portuguese women and should be an important target for health 
policy interventions.
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the ASSURE project. In this preliminary analysis, the comparative cost-effective-
ness of personalised screening strategies and current practice was calculated as 
a cost-per-case-detected from a health service perspective. Uncertainty in the 
cost-effectiveness estimate is investigated using one-way sensitivity analyses 
of key parameters. Results: The incremental cost-effectiveness ratio of a three 
risk group stratification procedure in the base case was £45,617 per-case-detected. 
Influential parameters were sensitivity of mammography, recall rate, cancer 
growth parameters and accuracy of risk estimation. cOnclusiOns: A very simple 
stratification procedure may not be cost-effective. The optimal risk stratification 
for personalised breast screening will be investigated to determine whether this 
offers improvement in cost-effectiveness.
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Objectives: Besides being associated with a negative impact on patients’ lives 
and a low 5-year survival rate[1], stage IV (metastatic) breast cancer is accompa-
nied with high treatment costs. The objective of this research was to analyse recent 
HTA decisions on metastatic breast cancer of different national HTA bodies world-
wide and investigate reasons for variances in their decision making. MethOds: 
Reimbursement decisions for metastatic breast cancer treatments across various 
national HTA bodies published between January 2013 and May 2015 were analysed. 
Factors such as variations in treatment guidelines, different disease mutations, 
specific lines of therapy or if the drug was a single or add-on treatment were not 
considered. Each HTA decision was analysed according to the following criteria: 
clinical value, survival benefit, price, ICER (where applicable), toxicity and quality 
of life. Treatments were not compared with each other, but the HTA evaluation of 
each treatment was considered across the single countries. Results: A review of 5 
breast cancer medications recently assessed independently across 9 HTA authori-
ties (6 European HTA bodies, Canada, Australia, Japan) showed that generally, 
drugs with sufficient proof of clinical value were nationally reimbursed. Positive 
reimbursement decisions for all treatments were made in Germany and France, 
while NICE and SMC only gave negative opinions. Most common reasons for non-
approvals or restrictions were “lack of cost effectiveness” and “lack of clinical 
value” in respectively 10 and 3 of the HTA submissions. cOnclusiOns: HTA deci-
sions for metastatic breast cancer treatments differ across countries, with some 
appearing to be more willing to reimburse medications. Clinical effectiveness was 
the most important decision factor for 5 countries, whereas cost-effectiveness 
was more relevant to the remaining 4 HTA bodies. With novel medications for 
metastatic breast cancer coming to market in the next years[2], certain criteria for 
HTA assessments might need to be re-defined. [1] http://www.cancer.org/cancer/
breastcancer/detailedguide/breast-cancer-survival-by-stage [2] http://ww5.komen.
org/BreastCancer/EmergingMetasticBreastCancer.html
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Objectives: Payers are seeking improvements in outcomes that are meaningful 
for the patient, but the preference of payers on what change can be considered 
meaningful is not well defined. Clinically relevant differences (CRDs) in outcomes 
and grading of their magnitude in oncology are being established by both European 
and American oncology organisations (European Society for Medical Oncology 
(ESMO) and American Society of Clinical Oncology (ASCO)). This indicates a transi-
tion from a focus primarily on statistical significant improvements (i.e., “is there 
a difference?”) in outcomes towards the clinical relevance of these improvements 
(i.e., “does the difference matter to patients?”). The attitude of payers towards 
CRDs in oncology outcomes is not well-understood, with little guidance around 
oncology CRDs from payers. The objective of this study is to evaluate the align-
ment between payers and clinicians in their assessment of clinical and health 
benefit of oncology products. MethOds: Oncology products launched recently 
were evaluated using the approach suggested by ESMO and ASCO. For the same 
products, the payer decision was evaluated to establish the clinical and health 
benefit rating by NICE (UK), HAS (France) and G-BA (Germany). Results: Not all 
products granted market approval have been evaluated by payers. The research 
showed that where they had been evaluated, payer quantification of clinical ben-
efit differed to that recommended by oncology societies. Furthermore, clinical 
benefit assessment, particularly regarding overall survival improvement, differed 
between payers themselves. cOnclusiOns: Oncology societies are recognising 
the need to ensure consistent assessment and representation of clinical benefit 
of new oncology products. Whilst payers often have guidance on how they assess 
benefit, this is often generic and applied across therapy areas. As a consequence, 
there still remains an inconsistent approach to evaluating clinical benefits in 
oncology between payers, which provides challenges and implications in drug 
development programmes for novel oncology therapies.
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Objectives: Cancer is the most common cause of mortality in England and Wales. 
This study investigated whether the number of technologies assessed by NICE for 
a specific cancer reflects its prevalence in England and Wales MethOds: 1-year 
elements more important to assessing value may improve these processes and 
contribute to giving a fairer access to appropriate treatments to patients.
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Objectives: The end-of-life consideration introduced by NICE in January 2009 allows 
extension of the upper limit of the cost-effectiveness thresholds beyond £30,000 per 
QALY for therapies that are indicated in patients with a short life expectancy and for 
small patient populations, with survival benefit of at least 3 months. The aim of this 
study was to assess the impact of the end-of-life considerations on health technol-
ogy assessment (HTA) recommendations for oncology therapies. MethOds: NICE 
single technology appraisals (STAs) for oncology therapies published between 2009 
and June 11, 2015 were assessed. End-of-life consideration, HTA recommendations, 
incremental cost-effectiveness ratio (ICER) values and the availability of patient access 
schemes were extracted. Results: A total of 53 STAs were identified during the study 
period and 20 appraisals/therapies met the end-of-life criteria. Maximum end-of-life 
considerations were granted in the year 2009 and 2012 (4 each), while 2013 to 2015 
recorded the minimum (2 each). Of the therapies meeting the end-of-life criteria, 13 
received positive recommendations with the ICER values ranging from £31,800 to 
£58,590. Highest percentage of positive recommendations were reported in the year 
2009 (100%), whereas no positive recommendations were recorded in 2013, which 
could be attributable to the high ICER values of the end-of-life therapies appraised in 
2013 (£40,000 to £100,000). In 2014 and 2015 each, 50% therapies (1/2) received positive 
recommendations. Of the 13 positive recommendations, 11 included patient access 
schemes by manufacturers. Unacceptably high ICER values followed by economic 
modelling issues leading to uncertain ICER values were major drivers of negative deci-
sions. cOnclusiOns: The use of end-of-life criteria for maximizing patient access 
remains suboptimal, as fewer treatments have met the end-of-life criteria in recent 
years. Also, increasing ICER values in end-of-life cancer appraisals have resulted in 
negative decisions. Patient access schemes by manufacturers may improve patients’ 
access to novel end-of-life oncology therapies.
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Objectives: A key challenge for successful introduction of new drugs in meta-
static breast cancer (MBC) is a positive health technology assessment (HTA) 
outcome across Europe. Thus, understanding of the MBC HTA landscape is essen-
tial. This study aims to identify key decision drivers and challenges for HTA in 
MBC. MethOds: An in-depth analysis of published HTA submissions in MBC over 
the last 5 years was conducted. In total, 96 HTA reports in MBC from 9 agencies 
were identified. Based on submission type and approval status, 38 HTA assess-
ments for 8 drugs were selected for further analysis. The analysis focussed on the 
submitted data and valuation by the different agencies. Outcomes were validated 
in an HTA expert meeting. Results: Of 38 HTA assessments, 11 received a nega-
tive recommendation, 8 a positive recommendation, and 13 a positive recom-
mendation with restrictions. The remaining 6 assessments were ongoing/did not 
provide a recommendation as yet. The majority of submissions included RCTs 
with PFS as primary endpoint and OS as secondary endpoint. HRQoL was not 
provided in 13/38 cases, with criticism in 8/38 cases. Some criticism was expressed 
regarding the logistics of HRQoL collection. The weight assigned to significance 
and incremental PFS and OS differed between countries. Twenty-eight of 38 sub-
missions included a PE evaluation. The key uncertainties in economic modelling 
related to validation of OS and PFS modelling (9/28) and the incorporation of 
safety data (11/28). Unfavourable ICERs and uncertainty in economic modelling 
were key drivers for negative decisions. cOnclusiOns: Gaining favourable HTA 
recommendation for new MBC drugs is challenging. In order to improve probability 
of successful introduction of a new MBC drug, demonstrating significant and clini-
cally meaningful incremental OS and/or PFS is key, as is providing strong HRQoL 
data. Moreover, well-validated PE model and acceptable ICERs are important to 
gain favourable HTA opinion.
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Objectives: This study estimates the cost-effectiveness of personalised breast 
cancer screening compared to one-size-fits-all screening. Personalised breast 
cancer screening has been proposed to both improve outcomes and screening 
programme efficiency. In a personalised screening programme frequency of 
mammography is varied based on women’s estimated risk of breast cancer. The 
Adapting Breast Cancer Screening Strategy Using Personalised Risk Estimation 
(ASSURE) project is a Europe-wide programme of work investigating new tech-
nologies and strategies in personalised screening. As there is substantial uncer-
tainty at this stage about several aspects of personalised screening the objective 
of this study is to provide information on which parameters are key in determin-
ing whether or not this strategy is cost-effective. MethOds: The structure of an 
economic model to assess the cost-effectiveness of personalised screening was 
developed with input from clinical experts. A preliminary proposal uses three risk 
groups with triannual, biannual and annual screening offered. The modelling tech-
nique of discrete event simulation was used to combine a natural history model 
of breast cancer, risk stratification procedures, screening processes and expected 
outcomes over a lifetime horizon. Parameters in this mathematical model were 
informed by previously published modelling studies and data gathered within 
